Medicine and Dentistry
Sorafenib
100%
Nivolumab
100%
Patient
100%
Lenvatinib
87%
Therapeutic Procedure
87%
Hepatocellular Carcinoma
62%
Overall Survival
37%
Mortality
25%
Neoplasm
12%
Follow up
12%
Lymph Node Metastasis
12%
Hazard Ratio
12%
Population Research
12%
Bilirubin
12%
Age
12%
Treatment Duration
12%
Survival
12%
Oncology
12%
Nursing and Health Professions
Sorafenib
100%
Nivolumab
100%
Lenvatinib
87%
Inpatient
75%
Overall Survival
37%
Mortality
25%
Follow up
12%
Confidence Interval
12%
Treatment Failure
12%
Tumor Volume
12%
Neoplasm
12%
Treatment Duration
12%
Bilirubin
12%
Lymph Node Metastasis
12%
Procedures
12%
Survival
12%
Laboratory
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sorafenib
100%
Nivolumab
100%
Lenvatinib
87%
Liver Cell Carcinoma
62%
Overall Survival
37%
Mortality
25%
Neoplasm
12%
Bilirubin
12%
Lymph Node Metastasis
12%
Survival
12%